[continued from previous message]
The interplay between the human body and our microbiomes is complex and our understanding of these relationships continues to evolve rapidly. Whether detectable changes in the bacterial ecology of the gastrointestinal tract of patients with CP/CPPS are
causative or resultant of the syndrome is unclear. At this time these differences are correlation. Given what we know currently about the role of microbiome and how it may affect systemic inflammation, modulate pain response and its putative role in
psychosocial stress, it is not impossible that the gut microbiome may play a role in the etiology of CP/CPPS. Perhaps initially this information may be used as a diagnostic tool to confirm a suspected case of CP/CPPS. Future investigation of changes in
the gut microbiome over time may be used to correlate with changes in symptoms and even aid in prognosticative (or phenotypically-driven) treatment approach. At the least, knowing these relationships exist lays the groundwork for further study in a novel
and rapidly developing area at the cross-section of laboratory science and clinical medicine.
AcknowledgementsOther Section
None.
FootnoteOther Section
Conflicts of Interest: Charis Eng is a member of the external strategic advisory board of N-of-One; Daniel A. Shoskes is a consultant to Farr Labs and stock ownership in Triurol. Hans C. Arora has no conflicts of interest to declare.
ReferencesOther Section
NIH HMP Working Group, Peterson J, Garges S, et al. The NIH Human Microbiome Project. Genome Res 2009;19:2317-23. [Crossref] [PubMed]
Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature 2007;449:804-10. [Crossref] [PubMed]
Schulberg J, De Cruz P. Characterisation and therapeutic manipulation of the gut microbiome in inflammatory bowel disease. Intern Med J 2016;46:266-73. [Crossref] [PubMed]
Geurts L, Neyrinck AM, Delzenne NM, et al. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benef Microbes 2014;5:3-17. [Crossref] [PubMed]
Gagnière J, Raisch J, Veziant J, et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 2016;22:501-18. [Crossref] [PubMed]
Rigoni R, Fontana E, Guglielmetti S, et al. Intestinal microbiota sustains inflammation and autoimmunity induced by hypomorphic RAG defects. J Exp Med 2016;213:355-75. [Crossref] [PubMed]
Moloney RD, Johnson AC, O’Mahony SM, et al. Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome. CNS Neurosci Ther 2016;22:102-17. [Crossref] [PubMed]
Winer DA, Luck H, Tsai S, et al. The Intestinal Immune System in Obesity and Insulin Resistance. Cell Metab 2016;23:413-26. [Crossref] [PubMed]
Xuan C, Shamonki JM, Chung A, et al. Microbial dysbiosis is associated with human breast cancer. PLoS One 2014;9:e83744. [Crossref] [PubMed]
Luna RA, Savidge TC, Williams KC. The Brain-Gut-Microbiome Axis: What Role Does It Play in Autism Spectrum Disorder? Curr Dev Disord Rep 2016;3:75-81. [Crossref] [PubMed]
Power C, Antony JM, Ellestad KK, et al. The human microbiome in multiple sclerosis: pathogenic or protective constituents? Can J Neurol Sci 2010;37 Suppl 2:S24-33. [Crossref] [PubMed]
Cryan JF, O’Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil 2011;23:187-92. [Crossref] [PubMed]
Diaz Heijtz R, Wang S, Anuar F, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci 2011;108:3047-52. [Crossref] [PubMed]
Di Bella JM, Bao Y, Gloor GB, et al. High throughput sequencing methods and analysis for microbiome research. J Microbiol Methods 2013;95:401-14. [Crossref] [PubMed]
David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505:559-63. [Crossref] [PubMed]
Wilcox MH. Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis. Best Pract Res Clin Gastroenterol 2003;17:475-93. [Crossref] [PubMed]
Beaugerie L, Petit JC. Microbial-gut interactions in health and disease. Antibiotic-associated diarrhoea. Best Pract Res Clin Gastroenterol 2004;18:337-52. [Crossref] [PubMed]
Antonopoulos DA, Huse SM, Morrison HG, et al. Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun 2009;77:2367-75. [Crossref] [PubMed]
Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 2011;108 Suppl 1:4554-61. [Crossref] [PubMed]
Krsmanovic A, Tripp DA, Nickel JC, et al. Psychosocial mechanisms of the pain and quality of life relationship for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Can Urol Assoc J 2014;8:403-8. [Crossref] [PubMed]
Roberts RO, Lieber MM, Rhodes T, et al. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 1998;51:578-84. [Crossref] [PubMed]
Murphy AB, Macejko A, Taylor A, et al. Chronic prostatitis management strategies. Drugs 2009;69:71-84. [Crossref] [PubMed]
Gardner WA Jr, Culberson DE, Bennett BD. Trichomonas vaginalis in the prostate gland. Arch Pathol Lab Med 1986;110:430-2. [PubMed]
Golz R, Mendling W. Candidosis of the prostate: a rare form of endomycosis. Mycoses 1991;34:381-4. [Crossref] [PubMed]
Doble A, Harris JR, Taylor-Robinson D. Prostatodynia and herpes simplex virus infection. Urology 1991;38:247-8. [Crossref] [PubMed]
Skerk V, Schönwald S, Granić J, et al. Chronic prostatitis caused by Trichomonas vaginalis--diagnosis and treatment. J Chemother 2002;14:537-8. [Crossref] [PubMed]
Brunner H, Weidner W, Schiefer HG. Studies on the role of Ureaplasma urealyticum and Mycoplasma hominis in prostatitis. J Infect Dis 1983;147:807-13. [Crossref] [PubMed]
Weidner W, Brunner H, Krause W. Quantitative culture of ureaplasma urealyticum in patients with chronic prostatitis or prostatosis. J Urol 1980;124:622-5. [PubMed]
Poletti F, Medici MC, Alinovi A, et al. Isolation of Chlamydia trachomatis from the prostatic cells in patients affected by nonacute abacterial prostatitis J Urol 1985;134:691-3. [PubMed]
Potts J, Payne RE. Prostatitis: Infection, neuromuscular disorder, or pain syndrome? Proper patient classification is key. Cleve Clin J Med 2007;74 Suppl 3:S63-71. [Crossref] [PubMed]
de la Rosette JJ, Ruijgrok MC, Jeuken JM, et al. Personality variables involved in chronic prostatitis. Urology 1993;42:654-62. [Crossref] [PubMed]
Naslund MJ, Strandberg JD, Coffey DS. The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol 1988;140:1049-53. [PubMed]
Kirby RS, Lowe D, Bultitude MI, et al. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol 1982;54:729-31. [Crossref] [PubMed]
Alexander RB, Brady F, Ponniah S. Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins. Urology 1997;50:893-9. [Crossref] [PubMed]
Hetrick DC, Ciol MA, Rothman I, et al. Musculoskeletal dysfunction in men with chronic pelvic pain syndrome type III: a case-control study. J Urol 2003;170:828-31. [Crossref] [PubMed]
Kaplan SA, Ikeguchi EF, Santarosa RP, et al. Etiology of voiding dysfunction in men less than 50 years of age. Urology 1996;47:836-9. [Crossref] [PubMed]
Hochreiter WW, Nadler RB, Koch AE, et al. Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology 2000;56:1025-9. [Crossref] [PubMed]
Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282:236-7. [Crossref] [PubMed]
Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology 1999;54:229-33. [Crossref] [PubMed]
Pontari MA. Chronic prostatitis/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment. Drugs Aging 2003;20:1111-25. [Crossref] [PubMed]
Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999;162:369-75. [
Crossref] [PubMed]
Propert KJ, Litwin MS, Wang Y, et al. Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Qual Life Res 2006;15:299-305. [Crossref] [PubMed]
Nickel JC, Downey J, Johnston B, et al. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial. J Urol 2001;165:1539-44. [Crossref] [PubMed]
Shoskes DA. Use of antibiotics in chronic prostatitis syndromes. Can J Urol 2001;8 Suppl 1:24-8. [PubMed]
Wagenlehner FM, Naber KG. Prostatitis: the role of antibiotic treatment. World J Urol 2003;21:105-8. [Crossref] [PubMed]
Taylor BC, Noorbaloochi S, McNaughton-Collins M, et al. Excessive antibiotic use in men with prostatitis. Am J Med 2008;121:444-9. [Crossref] [PubMed]
Nickel JC. Treatment of chronic prostatitis/chronic pelvic pain syndrome. Int J Antimicrob Agents 2008;31 Suppl 1:S112-6. [Crossref] [PubMed]
Shoskes DA, Hakim L, Ghoniem G, et al. Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. J Urol 2003;169:1406-10. [Crossref] [PubMed]
Nickel JC, Downey J, Ardern D, et al. Failure of a monotherapy strategy for difficult chronic prostatitis/chronic pelvic pain syndrome. J Urol 2004;172:551-4. [Crossref] [PubMed]
Shoskes DA, Nickel JC, Rackley RR, et al. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis 2009;12:177-83. [
Crossref] [PubMed]
Litwin MS. A review of the development and validation of the National Institutes of Health Chronic Prostatitis Symptom Index. Urology 2002;60:14-8; discussion 18-9. [Crossref] [PubMed]
Shoskes DA, Nickel JC, Dolinga R, et al. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology 2009;73:538-42. [Crossref] [PubMed]
Shoskes DA, Nickel JC, Kattan MW. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology 2010;75:1249-53. [Crossref] [PubMed]
Magri V, Marras E, Restelli A, et al. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Exp Ther Med 2015;9:658-66. [PubMed]
Babu PV, Liu D, Gilbert ER. Recent advances in understanding the anti-diabetic actions of dietary flavonoids. J Nutr Biochem 2013;24:1777-89. [Crossref] [PubMed]
de la Garza AL, Milagro FI, Boque N, et al. Natural inhibitors of pancreatic lipase as new players in obesity treatment. Planta Med 2011;77:773-85. [Crossref] [PubMed]
Etxeberria U, de la Garza AL, Campión J, et al. Antidiabetic effects of natural plant extracts via inhibition of carbohydrate hydrolysis enzymes with emphasis on pancreatic alpha amylase. Expert Opin Ther Targets 2012;16:269-97. [Crossref] [PubMed]
Siriwardhana N, Kalupahana NS, Cekanova M, et al. Modulation of adipose tissue inflammation by bioactive food compounds. J Nutr Biochem 2013;24:613-23. [Crossref] [PubMed]
Tang W, Li S, Liu Y, et al. Anti-diabetic activity of chemically profiled green tea and black tea extracts in a type 2 diabetes mice model via different mechanisms. J Funct Foods 2013;5:1784-93. [Crossref]
Shoskes DA, Zeitlin SI, Shahed A, et al. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999;54:960-3. [Crossref] [PubMed]
Shoskes DA. Use of the bioflavonoid quercetin in patients with longstanding chronic prostatitis. J Am Neutraceutical Assoc 1999;2:18-21.
Zhang M, Swarts SG, Yin L, et al. Antioxidant properties of quercetin. Adv Exp Med Biol 2011;701:283-9. [Crossref] [PubMed]
Rivera L, Morón R, Sánchez M, et al. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring) 2008;16:2081-7. [Crossref] [PubMed]
Waite KA, Sinden MR, Eng C. Phytoestrogen exposure elevates PTEN levels. Hum Mol Genet 2005;14:1457-63. [Crossref] [PubMed]
Heindl M, Händel N, Ngeow J, et al. Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology 2012;142:1093-6. [Crossref] [PubMed]
Chen HH, Händel N, Ngeow J, et al. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells. J Allergy Clin Immunol 2016. [Epub ahead of print]. [Crossref] [PubMed]
Ley RE, Bäckhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005;102:11070-5. [Crossref] [PubMed]
Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-31. [Crossref] [PubMed]
Cardona F, Andrés-Lacueva C, Tulipani S, et al. Benefits of polyphenols on gut microbiota and implications in human health. J Nutr Biochem 2013;24:1415-22. [Crossref] [PubMed]
Del Rio D, Rodriguez-Mateos A, Spencer JP, et al. Dietary (Poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal 2013;18:1818-92. [Crossref] [PubMed]
Etxeberria U, Arias N, Boqué N, et al. Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats. J Nutr Biochem 2015;26:651-60. [Crossref] [PubMed]
Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009;137:1716-24.e1-2.
Whiteside SA, Razvi H, Dave S, et al. The microbiome of the urinary tract--a role beyond infection. Nat Rev Urol 2015;12:81-90. [Crossref] [PubMed]
Jiang J, Knight J, Easter LH, et al. Impact of dietary calcium and oxalate, and Oxalobacter formigenes colonization on urinary oxalate excretion. J Urol 2011;186:135-9. [Crossref] [PubMed]
Kaufman DW, Kelly JP, Curhan GC, et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 2008;19:1197-203. [Crossref] [PubMed]
Siener R, Bangen U, Sidhu H, et al. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int 2013;83:1144-9. [Crossref] [PubMed]
Fredricks DN, Relman DA. Application of polymerase chain reaction to the diagnosis of infectious diseases. Clin Infect Dis 1999;29:475-86. [Crossref] [PubMed]
Tanner MA, Shoskes D, Shahed A, et al. Prevalence of corynebacterial 16S rRNA sequences in patients with bacterial and “nonbacterial” prostatitis. J Clin Microbiol 1999;37:1863-70. [PubMed]
Hochreiter WW, Duncan JL, Schaeffer AJ. Evaluation of the bacterial flora of the prostate using a 16S rRNA gene based polymerase chain reaction. J Urol 2000;163:127-30. [Crossref] [PubMed]
Krieger JN, Riley DE. Bacteria in the chronic prostatitis-chronic pelvic pain syndrome: molecular approaches to critical research questions. J Urol 2002;167:2574-83. [Crossref] [PubMed]
Krieger JN, Riley DE, Vesella RL, et al. Bacterial dna sequences in prostate tissue from patients with prostate cancer and chronic prostatitis. J Urol 2000;164:1221-8. [Crossref] [PubMed]
Keay S, Zhang CO, Baldwin BR, et al. Polymerase chain reaction amplification of bacterial 16s rRNA genes in prostate biopsies from men without chronic prostatitis. Urology 1999;53:487-91. [Crossref] [PubMed]
Floth A, Sunder-Plassmann G, Födinger M. Polymerase chain reaction amplification of bacterial 16s rRNA in biopsy samples. Urology 2000;55:788-9. [Crossref] [PubMed]
Leskinen MJ, Rantakokko-Jalava K, Manninen R, et al. Negative bacterial polymerase chain reaction (PCR) findings in prostate tissue from patients with symptoms of chronic pelvic pain syndrome (CPPS) and localized prostate cancer. Prostate 2003;55:105-10.
[Crossref] [PubMed]
Nickel JC, Stephens A, Landis JR, et al. Search for Microorganisms in Men with Urologic Chronic Pelvic Pain Syndrome: A Culture-Independent Analysis in the MAPP Research Network. J Urol 2015;194:127-35. [Crossref] [PubMed]
Dethlefsen L, Huse S, Sogin ML, et al. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008;6:e280. [Crossref] [PubMed]
Shoskes DA, Wang H, Polackwich AS, et al. Analysis of Gut Microbiome Reveals Significant Differences between Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Controls. J Urol 2016;196:435-41. [Crossref] [PubMed]
Shoskes DA, Altemus J, Polackwich AS, et al. The Urinary Microbiome Differs Significantly Between Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Controls as Well as Between Patients With Different Clinical Phenotypes. Urology 2016;92:
26-32. [Crossref] [PubMed]
Thomas-White KJ, Hilt EE, Fok C, et al. Incontinence medication response relates to the female urinary microbiota. Int Urogynecol J 2016;27:723-33. [Crossref] [PubMed]
Rudick CN, Jiang M, Yaggie RE, et al. O-antigen modulates infection-induced pain states. PLoS One 2012;7:e41273. [Crossref] [PubMed]
Malykhina AP. Neural mechanisms of pelvic organ cross-sensitization. Neuroscience 2007;149:660-72. [Crossref] [PubMed]
Braundmeier-Fleming A, Russell NT, Yang W, et al. Stool-based biomarkers of interstitial cystitis/bladder pain syndrome. Sci Rep 2016;6:26083. [Crossref] [PubMed]
Nickel JC, Stephens A, Landis JR, et al. Assessment of the Lower Urinary Tract Microbiota during Symptom Flare in Women with Urologic Chronic Pelvic Pain Syndrome: A MAPP Network Study. J Urol 2016;195:356-62. [Crossref] [PubMed]
Cite this article as: Arora HC, Eng C, Shoskes DA. Gut microbiome and chronic prostatitis/chronic pelvic pain syndrome. Ann Transl Med 2017;5(2):30. doi: 10.21037/atm.2016.12.32
Refbacks
There are currently no refbacks.
Article Options
Abstract
PDF
HTML
Download Citation
Bibtex
EndNote
ProCite
refMan
refWorks
Share
Share on Facebook
About
The Annals of Translational Medicine (Ann Transl Med; ATM; Print ISSN 2305-5839; Online ISSN 2305-5847) is an international, peer-reviewed Open Access journal featuring original and observational...
AME Publishing Company
AME Medical Journal
Annals of Blood
Annals of Cardiothoracic Surgery
Annals of Joint
Annals of Laparoscopic and Endoscopic Surgery
Annals of Palliative Medicine
Annals of Translational Medicine
Cardiovascular Diagnosis and Therapy
Chinese Clinical Oncology
Gland Surgery
Hepatobiliary Surgery and Nutrition
Journal of Gastrointestinal Oncology
Journal of Laboratory and Precision Medicine
Journal of Research Hospital
Journal of Thoracic Disease
Journal of Visualized Surgery
mHealth
Quantitative Imaging in Medicine and Surgery
Stem Cell Investigation
Translational Andrology and Urology
Translational Cancer Research
Translational Gastroenterology and Hepatology
Translational Lung Cancer Research
Translational Pediatrics
Video-Assisted Thoracic Surgery
Yan Ke Xue Bao
Links
DXY.CN
Biomart
Jobmd
The Prepared minds
theheart.org
The Beating Edge
Research Gate
Copyright © 2009 - 2017 Annals of Translational Medicine. All rights reserved.
http://atm.amegroups.com/article/view/13313/html
--- SoupGate-Win32 v1.05
* Origin: fsxNet Usenet Gateway (21:1/5)